Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

Executive Summary

RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.


Related Content

APOLLO Success Clears Alnylam For Lift-Off
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
How And Why Genzyme And Alnylam Expanded Their Alliance
Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
The Medicines Co. Enters PCSK9 Race With Alnylam Deal
Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement
Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates
Alnylam, Isis JV Regulus to Tackle MicroRNA


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts